Trial · NCT03200717
Results by group106
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 106
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Pazopanib- 2nd Line | 7.5 | 95% Confidence Interval 3.7 to 12.6 | Months | |
| Progression Free Survival (PFS) | Pazopanib- 3rd Line | 4.6 | 95% Confidence Interval 3.3 to 9.2 | Months | |
| Progression Free Survival (PFS) | All Participants | 6.8 | 95% Confidence Interval 3.7 to 11.1 | Months | |
| Overall Response Rate (ORR) Based on Local Investigator Assessment According to RECIST v1.1 | Pazopanib- 2nd Line | 23.4 | 95% Confidence Interval 12.3 to 38.0 | Percentage of participants | |
| Overall Response Rate (ORR) Based on Local Investigator Assessment According to RECIST v1.1 | Pazopanib- 3rd Line | 0 | 95% Confidence Interval 0.0 to 21.8 | Percentage of participants | |
| Overall Response Rate (ORR) Based on Local Investigator Assessment According to RECIST v1.1 | All Participants | 17.7 | 95% Confidence Interval 9.2 to 29.5 | Percentage of participants | |
| Clinical Benefit Rate (CBR) Based on Local Investigator Assessment According to RECIST v1.1. | Pazopanib- 2nd Line | 53.2 | 95% Confidence Interval 38.1 to 67.9 | Percentage of participants | |
| Clinical Benefit Rate (CBR) Based on Local Investigator Assessment According to RECIST v1.1. | Pazopanib- 3rd Line | 40.0 | 95% Confidence Interval 16.3 to 67.7 | Percentage of participants | |
| Clinical Benefit Rate (CBR) Based on Local Investigator Assessment According to RECIST v1.1. | All Participants | 50.0 | 95% Confidence Interval 37.0 to 63.0 | Percentage of participants | |
| Overall Survival (OS) | Pazopanib- 2nd Line | 27.8 | 95% Confidence Interval 14.9 to NA | Months | |
| Overall Survival (OS) | Pazopanib- 3rd Line | 20.0 | 95% Confidence Interval 9.2 to 25.6 | Months | |
| Overall Survival (OS) | All Participants | 23.4 | 95% Confidence Interval 14.9 to 31.8 | Months | |
| Duration of Response (DOR) Based on Local Investigators Assessment According to RECIST v1.1 | Pazopanib- 2nd Line | NA | 95% Confidence Interval 9.5 to NA | Months | |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 2 Day 1 | -1.3 | Standard Deviation 4.95 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 3rd Line | Cycle 2 Day 1 | -0.3 | Standard Deviation 4.31 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 2 Day 1 | -1.0 | Standard Deviation 4.78 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 3 Day 1 | -0.5 | Standard Deviation 4.55 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 3rd Line | Cycle 3 Day 1 | 1.7 | Standard Deviation 4.18 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | All Participants | Cycle 3 Day 1 | -0.0 | Standard Deviation 4.51 | Score on a scale |
| Change From Baseline in Functional Assessment of Cancer Therapy- Kidney Symptom (FKSI-DRS) Score | Pazopanib- 2nd Line | Cycle 4 Day 1 | -0.1 | Standard Deviation 2.97 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03200717/results